Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023418 (leukemia)
 93,477 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Two clonal leukemia cell lines exhibiting diploidy or tetraploidy were isolated separately from a mother cell population of rat myelogenous leukemia DBLA-6 (induced by 1-butyl-1-nitrosourea), and their biologic characteristics altered during serial iv or ip passages in Donryu rats were examined. In early generations after the establishment of the clones, leukemia-inducing capacities were clearly demonstrated only in the diploid clone and were characterized as follows: a) release of leukemia cells into the peripheral blood after inoculation, and b) infiltration, and growth of leukemia cells in the bone marrow and spleen. After repeated iv passages, however, leukemia-inducing capacity was greater not only in the diploid but also in the tetraploid clone. By serial ip passages, this capacity was never acquired but was gradually lost even in the diploid clone. Cell electrophoretic mobility, cell size, or susceptibility to chemotherapeutic agents were also modified. There was a strong correlation between the routes of passage and the direction of the changes: The iv route enhanced or the ip route suppressed the leukemia-inducing capacity. Chromosome constitutions were also changed.
 ...
PMID:Alteration of biologic behavior of a rat leukemia by different routes of passage. 106 26

The oral administration of N, N'-2,7-fluorenylenebisacetamide induced leukemia, especially mature granulocytic leukemia, in rats. The peripheral blood was examined on various schedules, once or twice a week for a long term. The blood volume lost by a blood collection was little, but it was not negligible in small animals such as rats when the loss was repeated. We investigated the relationship between the volume of blood loss and the incidence of leukemia. The incidence of leukemia rose as the volume of blood loss increased. There was a positive correlation between them. The induction of mature granulocytic leukemia was thought to be increased by the promotion of the granulopoiesis which had been suppressed by 2,7-FAA. It was concluded that the blood loss by repeated blood collection for examination raised the incidence of 2,7-FAA induced leukemia.
 ...
PMID:Influence of blood collection on incidence of 2,7-FAA induced rat leukemia. 106 84

Observations in six adult patients with leukaemic differential white counts, predominantly mature-celled, and with hepatosplenomegaly show that the mature-celled but fulminant (para-)neutrophil leukaemia must be differentiated from Ph1-positive chronic myeloid leukaemia. This (para-)neutrophil leukaemia is probably identical with the previously described atypical chronic myelosis of the adult, chronic myeloid leukaemia of childhood and the Pelger-like chronic myeloid leukaemia. Cardinal signs are a mature-celled differential count, short life expectancy (1 year), initial platelet deficiency, increased activity of granulocyte alkaline phosphatase, absence of Ph1-chromosome, and poor therapeutic response to busulfan. This curious and yet apparently not uncommon disease has been observed in the adult age group predominantly in men. The frequently high HbF level observed in juvenile chronic myeloid leukaemia could not be demonstrated in adults. Some of these neutrophil leukaemias are characterized by medullary fibrosis and terminal increase of immature blast cells (blast crises?) of which the diagnostic reliability is still disputed.
 ...
PMID:[Differential diagnosis of atypical chronic myeloid leukaemia]. 106 23

The juvenile type of "chronic myelogenous" leukemia (CMLJT) is a rare disease with only 40 cases reported to date. Clearly distinguishable from adult CML on both clinical and laboratory grounds, is is often confused with "congenital" leukemia, pseudoleukemia, leukemoid reactions or chronic granulomatous disease. According to studies of muramidasuria and colony-forming cells it is neither a chronic nor a granulocytic leukemia. It is a panmyelopathy with monocyte predominance and should thus be classified as a variant of myelo-monocytic leukemia. We review reported responses to chemotherapy and splenectomy and report our results with cytosine arabinoside in the treatment of 2 cases with this disease. Chemotherapy may prolong life and splenectomy may be useful in some cases; but the survival rate is 0%, justifying new approaches.
 ...
PMID:"Chronic myelogenous" leukemia of juvenile type. Report of two cases and review of therapy. 106 53

No more than 150 cases of neonatal leukemia had been reported in the literature. Seven additional cases are reported herein. The incidence of neonatal leukemia has been of one in 50,000. Its incidence among the group of neonates requiring hospitalization has been of 0.075%. The seven neonates with leukemia consist of five males and two females. Two of them had an associated Down's syndrome. Abdominal distension, hepatomegaly, splenomegaly, cutaneous manifestations and purpura were the most frequent clinical findings in our patients. Severe anemia was present in only three patients. Thrombocytopenia was recognized in six of them. A high white blood cell count was present in five patients. The number of blast cells in their peripheral blood smear ranged between 16 and 100%. A remarkable myeloid dominance was observed. One patient died two hours after birth and his diagnosis was made at autopsy. Three patients were diagnosed before the age of three weeks. The three patients with myeloid leukemia were treated with DNR and Ara-C. A complete hematological remission was achieved in two of them. One patient died of a Pn. carinii pneumonia one month after the remission was induced. The remainder patient of this group had a Down's syndrome and the leukemia had been confirmed by hepatic biopsy. After two years of maintenance with Ara-C and Thioguanine he is alive and both, peripheral blood and bone marrow, remains normal. A lymphocitic leukemia was seen in only two patients. One was treated with prednisolone and VCR, and the other with prednisolone, VR and L-Asp. In both cases a good response to the chemotherapy was observed. Autopsy was performed in all patients who died but one. The pathological findings are analyzed. The low survival among patients with neonatal leukemia may be influenced by the toxic side effects of the used chemotherapy. All aspects of the medical treatment including drugs of choice and the usefullness of isolation devices are further discussed.
 ...
PMID:[Neonatal leukemia. Report of seven cases (author's transl)]. 106 63

Simian antisera to human leukemia cells were able to distinguish antigens specific for lymphocytic types of leukemia from those expressed on certain myeloid leukemia cells. In this investigation, cells from acute myelomonocytic leukemia patients (AMML) were examined for their membrane-associated leukemia antigens. Simian antisera to both lymphocytic and myelogenous leukemia cells lysed cells from AMML donors. Monkey antisera to AMML cells, by direct microcytotoxicity testing, were cytotoxic for cells from all AMML patients, as well as for cells of certain patients with myeloid leukemia. Cells from patients with lymphatic leukemia were nonreactive. However, absorption studies indicated an antigen present on cells from patients with chronic lymphocytic leukemia which cross-reacted with AMML cell antigens. Sequential analyses of the serologic reactivity of cells from AMML patients undergoing chemotherapy corresponded with the clinical course of the patient, even though there was little correlation between the percentage of blast cells present and the per cent cytotoxicity with the antisera. At certain times a higher percentage of seropositive cells could be detected over that seen on morphological evaluation. The estimation of leukemic cells by serologic means could aid in the diagnosis and management of AMML patients during chemotherapy.
 ...
PMID:Human acute myelomonocytic leukemia: serologic studies with simian antisera. 106 71

The oral administration of N,N'-2,7-fuorenylenebisacetamide (2,7-FAA) induced leukemia, especially mature granulocytic leukemia, in rats. 2,7-FAA was administered to the rats of the Wistar strain and a small amount of bloodletting was repeated for a long period. The incidence of leukemia and mature granulocytic leukemia became elevated by bloodletting. The induction of mature granulocytic leukemia might be increased by the promotion of granulopoiesis which had been suppressed by 2,7-FAA.
 ...
PMID:Effect of repeated bloodletting on the incidence of 2,7-FAA-induced rat leukemia. 106 28

Rabbit antisera to myelogenous leukemia (ML) cells were raised; ML cells from line K-562 that has the Philadelphia (Ph) chromosome were used as antigen. Antibodydependent, complement-mediated cytotoxicity was demonstrated by the trypan blue test and Cr release assay for cultured ML cells, whereas no cytotoxicity was demonstrated for cells from B (SB) and T (MOLT 4) lymphoblastoid cell lines. The antisera showed no cross-reactivity for normal human peripheral leukocytes or purified granulocytes. A low level (less than 8%) of cytotoxicity was directed against cell membrane associated fetal bovine serum proteins. Absorption of the immune serum with normal human bone marrow cells of first trimester human whole embryo cells reduced the cytotoxic titer to a similar extent; this suggested the possibility of crossreactivity between ML cells and fetal antigen(s). However, the ML antigen(s) was unrelated to carcinoembryonic antigen (CEA), since absorption with CEA had no effect on the serum cytotoxic titer. The anti-ML sera were cytotoxic for cells taken from 10 patients with chronic myelogenous leukemia and from 3 with acute myelogenous leukemia. In contrast, the leukocytes of 1 of 4 patients with acute lymphocytic leukemia, and 3 of 7 with chronic lymphocytic leukemia shared similar antigenic determinants as demonstrated by cytotoxicity tests. The significance of the cross-reactivity of some lymphatic and ML cells may be the result of the use of rabbit sera that did not distinguish antigens common to both granulocytic and lymphocytic cells, or it may reflect an "immature" or "blastic" antigen present on many leukemia cells.
 ...
PMID:Cytotoxicity of antisera to a myelogenous leukemia cell line with the Philadelphia chromosome. 106 37

To understand further the hematopoietic dyscrasias induced by a variant (a) of Rauscher leukemia virus (RLV), we used Escherichia coli endotoxin to stress the hematopoietic system of control and RLV/a-infected BALB/c mice. During the preleukemic stages of virus infection, there was slight splenomegaly without peripheral blood erythroblastosis. Granulocyte release and tissue mobilization mechanisms appeared unaffected by the RLV/a infection. Both RLV/a-infected and control mice reacted to endotoxin with peripheral granulocytosis and peritoneal granulocyte mobilization, though the circulating granulocyte levels in RLV/a-treated mice initially were lower than those in controls. Spleen of RLV/a-infected animals were larger than those of controls, but both responded to endotoxin with elevated numbers of granulocytes and erythroblasts. Since numbers of bone marrow erythroblasts in both groups of mice were decreased after endotoxin, stem cell competition and/or shunting of stem cells from marrow to spleen may have been involved. Endotoxin also induced rapid falls in hematocrit levels in both groups. These studies suggested that RLV/a-infected mice can be a model to study 1) erythropoietic dysfunction uncomplicated by defective granulopoietic release and tissue mobilization control mechanisms, and 2) progression of evolving granulocytic leukemia.
 ...
PMID:Granulopoiesis in "preleukemic" mice with anemia induced by Rauscher leukemia virus, variant a. 110 69

Twenty-seven novel nucleobases and nucleosides were synthesized by structural modification of uracil, and their effects on growth and differentiation of human myeloid leukemia HL-60 cells were examined. Some of the compounds inhibited the growth of HL-60 effectively. The nitroblue tetrazolium (NBT)-reducing activities of cells treated with the concentrations of these compounds for 50% inhibition of growth were compared. TI-66 (2,4-dibenzyl-6-fluoro-7,7,8,8-tetramethyl-cis-2,4-diazabicyclo-[4.2.0] octane-3,5-dione) was the most effective inducer of NBT-reducing activity and morphological differentiation of HL-60 cells into cells of the myelomonocytic lineage. TI-66 was also effective for induction of differentiation of another human myelogenous leukemia cell line, ML-1 cells, but not for differentiation of human erythroid leukemia K562 or HEL cells, or monocytic U937 cells. The effect of TI-66 in inducing differentiation of HL-60 cells was additive or more than additive in combination with retinoic acid or vitamin D3. Adenine or hypoxanthine alone induced NBT-reducing activity of the cells, and at suboptimal concentrations these compounds enhanced the effect of TI-66, but the enhanced NBT-reducing activities did not exceed the maximal activity induced by TI-66 alone. Simultaneous treatment of HL-60 cells with hypoxanthine reduced the growth inhibition by TI-66 alone. TI-66 was about 150 times more potent on a molar basis than adenine in inducing differentiation of HL-60 cells. These results suggest that nucleobase analogs such as TI-66 should be useful for differentiation therapy of some types of myelogenous leukemia.
 ...
PMID:Effects of novel uracil analogs on proliferation and differentiation of human myeloid leukemia cells. 132 Oct 51


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>